ascopubs.org

Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer

Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches A model of absolute risk ...
Business Wire

Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV events

Successful topline results from the CLEAR Outcomes Trial demonstrate that bempedoic acid, marketed as NILEMDO ® in Europe, reduces the risk of serious cardiovascular (CV) events in patients with, or ...
MedPage Today on MSN

How much efficacy do statin users demand in primary prevention?

Study indicates daunting numbers ...
The American Journal of Managed Care

Relative Benefit in Survival, Reduction in TE/MAVE Risk With Eculizumab for Patients With PNH

When patients with paroxysmal nocturnal hemoglobinuria (PNH) received eculizumab, survival rates increased and thromboembolic events/major adverse vascular events (TE/MAVE) decreased. Eculizumab ...